Trapidil Therapy for Drug-Induced Extrapyramidal Syndromes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for extrapyramidal syndromes, such as dyskinesia and dystonia, are inadequate in managing drug-induced movement disorders, which affect a significant portion of patients and can lead to severe quality of life issues and adverse drug reactions.
Innovation Solution
The use of Trapidil, its derivatives, metabolites, prodrugs, analogs, or pharmaceutically acceptable salts, alone or in combination with additional therapeutic agents, to modulate markers associated with extrapyramidal syndromes, such as ERK pathway activity and inflammatory markers, thereby reducing the symptoms of these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for extrapyramidal syndromes are used, then the basic symptom management is achieved, but the quality of life remains severely impacted and adverse drug reactions persist
Solution Approach 1:
The patent applies parameter changes by targeting and modulating specific molecular markers (such as ERK pathway activity and inflammatory markers) associated with extrapyramidal syndromes. By changing the pharmacological parameters to specifically address these molecular targets, the treatment achieves more effective symptom management while reducing adverse effects compared to conventional approaches.
Solution Approach 2:
The patent uses Trapidil as an intermediary substance that modulates the markers associated with extrapyramidal syndromes. This intermediary approach allows for more precise control of the disease mechanism, improving treatment effectiveness while minimizing direct harmful effects on the patient.
2Productivity
If existing therapeutic agents are administered, then movement disorder symptoms are partially controlled, but the frequency and severity of symptoms persist
Solution Approach 1:
The patent employs feedback mechanisms by monitoring and modulating specific molecular markers (such as ERK pathway activity and inflammatory markers) to dynamically adjust treatment effectiveness. This feedback approach enables more sustained symptom control by continuously optimizing the therapeutic response.
Solution Approach 2:
The patent utilizes combination therapies involving Trapidil administered with or without additional therapeutic agents. This composite approach combines the effects of multiple substances to achieve more durable and effective symptom control than single-agent treatments.
Data Source
AI summary
Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.